Related Experiment Video
Updated: May 3, 2026
05:31
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
1.4K
[Predictive value of placenta-derived RASSF1A sequence expression in maternal plasma for pre-eclampsia]
Jian Wang1, Jing Yang, Xiaohong Wu
1Institute of Immunology, Shanxi Datong University, Datong, Shanxi 037009, P.R.China. dtyzfx@163.com.
Summary
Hypermethylated RASSF1A gene in maternal plasma can predict pre-eclampsia. Elevated levels in the second trimester indicate higher risk, aiding early detection and management of this pregnancy complication.
Area of Science:
- Reproductive biology
- Genetics
- Biomarker discovery
Context:
- Pre-eclampsia is a serious pregnancy complication.
- Early prediction of pre-eclampsia is crucial for maternal and fetal health.
- Placenta-derived genes in maternal circulation are potential biomarkers.
Purpose:
- To investigate the expression of placenta-derived RASSF1A gene in maternal plasma during pregnancy.
- To explore the utility of RASSF1A gene expression for predicting pre-eclampsia.
Summary:
- This study analyzed hypermethylated RASSF1A gene concentrations in maternal plasma from 325 pregnant women using methylation-sensitive restriction enzyme digestion and quantitative PCR.
- Significantly higher RASSF1A levels were observed in the second trimester (13-24 weeks) in women who later developed pre-eclampsia compared to controls.
- Concentrations differed between mild and severe pre-eclampsia, and between early-onset and late-onset severe pre-eclampsia.
Impact:
- Altered RASSF1A gene expression in maternal plasma during the second trimester shows potential for early pre-eclampsia prediction.
- This finding could lead to improved screening strategies and timely interventions for pre-eclampsia.
- Further research can validate RASSF1A as a reliable non-invasive biomarker for pre-eclampsia risk assessment.
